Status:
UNKNOWN
Effectiveness of Iguratimod Versus Placebo to Treat Early Rheumatoid Arthritis on MRI
Lead Sponsor:
Jiangsu Simcere Pharmaceutical Co., Ltd.
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the efficacy of Iguratimod versus placebo on synovial inflammation,bone erosion and bone edema as measured by MRI of wrist and Metacarpophalangeal joints in pa...
Detailed Description
Magnetic resonance imaging (MRI) is a powerful imaging modality that is now widely used in both scientific research and clinical settings to visualise joints of patients with RA. MRI is able to image ...
Eligibility Criteria
Inclusion
- Subjects with a diagnosis of RA according to the diagnostic criteria of the American College of Rheumatology (ACR) (revised in 1987)
- Rheumatoid Arthritis for 3 months to 2 years from the time of the initial diagnosis
- Functional Class II-III
- Subjects have active RA at the time of screening
- Must have a negative Pregnancy test and use adequate method of contraception throughout the trial
- Must have at least 4 tender joints and 4 swollen joints(involved in DAS28) and among these,at least one swollen Metacarpophalangeal joint is essential
- Has a C-reactive protein ≥ 10 mg/L OR Erythrocyte Sedimentation Rate (ESR) ≥ 28 mm/hr
- Written informed consent
Exclusion
- Preceding treatment with DMARDs, immunosuppressants (cyclophosphamide, cyclosporine, azathioprine, etc.), biological agents or tripterygium within 12 weeks prior to study entry
- Chest x-ray abnormalities, such as tuberculosis, interstitial pulmonary fibrosis, etc
- ALT \>1.5×ULN, AST \>1.5×ULN, Cr \>135umol/L or Cr \>1.5mg
- WBC\<4×109/L，HGB\<85g/L，PLT\<100×109/L
- Subjects with serious cardiovascular, renal, hematologic,endocrine diseases or malignant
- Subjects with immunodeficiency, uncontrolled infection and active gastrointestinal disease
- Pregnant, intend to become pregnant, or are breastfeeding
- Subjects with other rheumatological diseases such as SLE, mixed connective tissue disease, scleroderma, polymyositis, etc
- Subjects with inflammatory arthritis, such as gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease
- Subjects with intra-articular corticosteroid injections within 6 weeks prior to study entry
- Allergic to any of the study drugs
- History of alcoholism
- Subjects with mental illness
- Subjects receiving live vaccines recently
- Subjects participating in other clinical study within 3 months prior to study entry
Key Trial Info
Start Date :
July 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2015
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01893151
Start Date
July 1 2012
End Date
December 1 2015
Last Update
October 23 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Third Affiliated Hospital Of Sun Yat-sen University
Guangzhou, Guangdong, China, 510630